Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock.

CAPR has been the topic of several other research reports. StockNews.com cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. LADENBURG THALM/SH SH raised their price target on Capricor Therapeutics from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Oppenheimer assumed coverage on Capricor Therapeutics in a report on Friday, May 17th. They set an “outperform” rating and a $14.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $21.75.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $4.83 on Tuesday. The stock has a fifty day moving average price of $5.36 and a two-hundred day moving average price of $5.15. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $8.22. The firm has a market capitalization of $154.46 million, a P/E ratio of -5.55 and a beta of 4.00.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Monday, May 13th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.20). Capricor Therapeutics had a negative net margin of 89.72% and a negative return on equity of 231.68%. The business had revenue of $4.91 million during the quarter, compared to analyst estimates of $10.00 million. On average, equities research analysts predict that Capricor Therapeutics will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the 1st quarter valued at approximately $40,000. Citigroup Inc. acquired a new stake in Capricor Therapeutics in the 3rd quarter valued at approximately $211,000. Jump Financial LLC acquired a new stake in Capricor Therapeutics in the 4th quarter valued at approximately $258,000. Finally, Vanguard Group Inc. raised its position in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.